France· FR:62048742
EFLUELDA, suspension injectable en seringue préremplie.Vaccin grippal trivalent (inactivé, à virion fragmenté), 60 microgrammes HA/souche
A medicinal product, registered in France by SANOFI WINTHROP INDUSTRIE, on the national reimbursement list.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Manufacturer
- SANOFI WINTHROP INDUSTRIE
- Country
- France (FR)
- ATC code
- —
- Reimbursed
- Yes
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- June 3, 2026
Packs & prices · 1
1 priced- cip1334009303050101 seringue préremplie en verre de 0,5 mL avec aiguilleEUR 23.97
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b3b29c1b-b262-4559-821f-dd7fc8fe38fb GET /v1/drugs/b3b29c1b-b262-4559-821f-dd7fc8fe38fb?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "62048742",
"date_amm": "2024-10-28",
"type_amm": "Procédure décentralisée",
"numero_ue": null,
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "suspension injectable",
"voies_administration": "intramusculaire;sous-cutanée",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Oui"
}See everything about EFLUELDA.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.